FibroGen Inc. (FGEN)
0.30
-0.00 (-0.03%)
At close: Apr 02, 2025, 10:03 AM
-0.03% (1D)
| Bid | 0.3 |
| Market Cap | 30.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -0.2 |
| Forward PE | -1.29 |
| Analyst | Buy |
| Ask | 0.31 |
| Volume | 221,558 |
| Avg. Volume (20D) | 3,563,420 |
| Open | 0.30 |
| Previous Close | 0.30 |
| Day's Range | 0.29 - 0.31 |
| 52-Week Range | 0.18 - 2.15 |
| Beta | 0.83 |
About FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 14, 2014
Employees 225
Stock Exchange NASDAQ
Ticker Symbol FGEN
Website https://www.fibrogen.com
Analyst Forecast
According to 1 analyst ratings, the average rating for FGEN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 3247.84% from the latest price.
Stock Forecasts2 weeks ago
-21.8%
FibroGen shares are trading lower. The company rep...
Unlock content with
Pro Subscription
1 month ago
+37.44%
FibroGen shares are trading higher after the company announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.
